Short-Term Outcomes of Bimatoprost Sustained-Release Intracameral Implant in Glaucoma

• Published in: Journal of glaucoma Vol. 32; no. 9; pp. 738 - 743
• Main Authors: Wong, Michael K, Bowers, Mallory E, Ventimiglia, Jonas, Niknam, Rachel M, Moster, Marlene R, Pro, Michael J, Dale, Elizabeth, Kolomeyer, Natasha N, Lee, Daniel, Zheng, Cindy X
• Format: Journal Article
• Language: English
• Published: United States 01-09-2023
• ISSN: 1057-0829; 1536-481X
• DOI: 10.1097/IJG.0000000000002271

This retrospective study found a statistically significant reduction in mean intraocular pressure and number of medications after intracameral Bimatoprost SR injection in patients with glaucoma. A history of selective laser trabeculoplasty did not impact treatment outcomes.
To determine outcomes of Bimatoprost sustained release (Bimatoprost SR) on intraocular pressure (IOP) and number of topical IOP lowering medications in patients with glaucoma. A secondary objective was to determine the outcomes of Bimatoprost SR in patients with a prior history of selective laser trabeculoplasty (SLT).
Retrospective case series. One hundred and eighteen eyes from 84 patients that received Bimatoprost SR by 6 glaucoma specialists at Wills Eye Hospital from March 2020 to September 2021 were examined. The intervention was a single injection of intracameral Bimatoprost SR. Main outcome measures included IOP and number of medications.
The mean most recent follow-up time for all eyes was 27.8±18.6 weeks. Mean post-treatment IOP at most recent follow-up of 16.6±5.3 mmHg was significantly lower than mean under therapy pre-treatment IOP of 18.5±5.7 mmHg for all eyes (P<0.01). Mean post-treatment number of medications at most recent follow-up of 1.3±1.3 decreased compared to number of pre-treatment medications of 2.1±1.4 for all eyes (P<0.01). Analysis of multilevel models controlling for demographic variables demonstrated a statistically significant reduction in IOP and number of medications post-treatment (P<0.01). A prior history of SLT (n=54) had no impact on treatment for both IOP and number of medications (P>0.1 for both).
Intracameral Bimatoprost SR reduced IOP and decreased the number of medications. Prior history of SLT did not impact Bimatoprost SR treatment outcomes.